Last updated: April 26, 2026
What is the commercial supply model for hydrocodone bitartrate and ibuprofen?
Hydrocodone bitartrate and ibuprofen typically enter pharmaceutical supply chains through two layers:
- Drug substance (API) suppliers licensed to manufacture controlled or non-controlled active ingredients under GMP.
- Finished dosage manufacturers (tablets/capsules) that source APIs and package to label and regulatory requirements.
For hydrocodone bitartrate, supply is constrained by DEA-controlled substance handling, quota/registration, and diversion-control programs. For ibuprofen, supply is broader because it is non-controlled in most major jurisdictions.
Hydrocodone Bitartrate (API + finished-dose supply): who supplies it?
Hydrocodone bitartrate is a controlled opioid. In practice, reputable supply comes from GMP-compliant API manufacturers and regulated finished-dose producers with DEA registrations, controlled-substance logistics, and audit-ready documentation (CoA, batch records, impurity profiles, residual solvent and elemental impurity compliance).
Common supplier base for hydrocodone bitartrate includes:
- Teva Pharmaceutical Industries (API and/or finished products in the opioid analgesic supply chain)
- Mylan (Viavi/Mylan brand history; now Viatris) (opioid analgesic supply for multiple markets)
- Sandoz (opioid analgesic footprint through finished products in several markets)
- Mallinckrodt (opioid product manufacturing and supply for branded and generic analgesics)
- Purdue Pharma legacy manufacturing network (relevant historically to hydrocodone analgesics; current supply depends on current product/market obligations)
Important: The hydrocodone market is dominated by finished-dose manufacturers because drug-product supply is what payers and wholesalers contract for. API sourcing can vary by lot, market authorization, and regulatory pathway.
Ibuprofen (API + finished-dose supply): who supplies it?
Ibuprofen is widely available because it is non-controlled and has extensive global chemical manufacturing capacity. Ibuprofen APIs and finished-dose products come from large generic and specialty chemical/pharma manufacturers.
Common supplier base for ibuprofen includes:
- BASF (global chemical supplier footprint for industrial and pharma-grade actives; ibuprofen supply is tied to grade and regulatory status by market)
- Bayer (historical originator manufacturing and ongoing supply in select channels)
- Teva (generic finished-dose and supply chain presence across analgesics)
- Viatris (Mylan legacy) (generic analgesics footprint)
- Sandoz (generic analgesics footprint)
- Dr. Reddy’s Laboratories (API and/or finished-dose distribution in multiple markets)
- Sun Pharmaceutical Industries (API and/or finished-dose presence)
What suppliers matter most for deal execution?
From a contracting standpoint, companies and investors typically screen suppliers against five criteria:
- GMP certification and scope
- API manufacturing site GMP status for the active ingredient
- Finished-dose manufacturing site GMP status if outsourcing tablets/capsules
- Regulatory authorization
- ANDA/EMA registration linkage for finished products where applicable
- Controlled-substance compliance (hydrocodone)
- DEA registration and quota fulfillment for US shipments
- auditing, diversion controls, secure logistics
- Quality documentation
- CoA per batch, impurity profile, ICH limits, residual solvents, elemental impurities
- Supply continuity
- multi-source capability, change control, and batch-to-batch consistency
Supplier short-list framing by route to market
For finished-dose procurement (tablets/capsules)
Finished-dose sourcing is usually the fastest path for commercial launch because packaging, labeling, and regulatory compliance are packaged into the purchase agreement.
- Hydrocodone bitartrate products: shortlist finished-dose manufacturers with a history in opioid analgesics distribution and confirmed controlled-substance handling.
- Ibuprofen products: shortlist finished-dose manufacturers with broad analgesics manufacturing capacity and a track record of generic supply continuity.
For custom development and clinical supply (API + dosage)
- Hydrocodone bitartrate development: prioritize API suppliers with controlled-substance handling and validated impurity controls; then pair with a dosage manufacturer experienced in opioid formulations.
- Ibuprofen development: prioritize API and dosage suppliers with proven dissolution stability, polymorph/grade control, and documented bioequivalence support (if required).
Supplier due-diligence checklist (contract-ready)
The following items typically drive supplier qualification and reduce batch rejection risk:
| Qualification axis |
What to verify |
Why it matters |
| API GMP scope |
Site covers hydrocodone bitartrate or ibuprofen |
Avoids scope mismatch that blocks release |
| Controlled-substance capability (hydrocodone) |
DEA registration, secure logistics SOPs |
Prevents compliance failure in shipping and warehousing |
| Impurity control |
Identified and quantified impurities, routes, and limits |
Hydrocodone impurities drive safety and release decisions |
| Stability and handling |
Storage conditions, temperature excursion controls |
Impacts shelf-life and potency |
| Regulatory history |
Whether the supplier has supported ANDA/EMA submissions |
Speeds documentation acceptance |
Key Takeaways
- Hydrocodone bitartrate supply is constrained by controlled-substance compliance and typically executes through licensed opioid finished-dose manufacturers backed by GMP API sourcing.
- Ibuprofen supply is broader and largely executes through multi-site GMP API and finished-dose networks with less regulatory friction.
- Contracting and R&D timelines hinge on GMP scope fit, impurity control documentation, and (for hydrocodone) DEA-controlled logistics capability.
FAQs
-
Is hydrocodone bitartrate supply harder than ibuprofen?
Yes. Hydrocodone bitartrate is controlled, so sourcing depends on DEA/quota and diversion-control compliance, while ibuprofen is non-controlled in most regimes.
-
Should we source hydrocodone bitartrate as API or finished dosage?
Finished-dose sourcing usually reduces execution risk because formulation, packaging, and compliance documentation are bundled.
-
What quality documents are required for API release?
Batch CoA, impurity profile, residual solvents and elemental impurity reports, and GMP batch records aligned to product specifications.
-
What increases batch rejection risk for hydrocodone products?
Impurity excursions, inadequate controlled-substance traceability, and documentation gaps around handling and testing can block release.
-
Why do multiple ibuprofen suppliers exist?
Ibuprofen has broad global chemical manufacturing capacity and is widely available as API and finished dosage, enabling price and supply competition.
References
[1] US Drug Enforcement Administration (DEA). Controlled Substances Act and DEA registration requirements.
[2] FDA. Current Good Manufacturing Practice (CGMP) requirements for drugs and APIs.
[3] ICH. Q3A/Q3B/Q3C and impurity guidance for pharmaceuticals.
[4] FDA. Drug product and API quality and regulatory expectations (CGMP and quality system frameworks).
